DHM SAFETY PROFILE

What the Short-Term Human Data Shows

The NIH LiverTox database, which is the canonical reference for hepatotoxicity of dietary supplements, lists DHM as not having been linked to instances of serum enzyme elevations or clinically apparent liver injury¹. The few short-term human trials of DHM that have been published reported no adverse events. There are no clinical case reports of liver injury attributed to DHM specifically, and DHM is not listed in the major systematic reviews of herbal-and-dietary-supplement induced liver injury¹². The short-term clinical safety record is clean, in the limited human trial data we have so far at least.

What the Animal Toxicity Studies Show

Animal toxicology work on DHM is more extensive than the human data, and it is consistently favorable. Acute toxicity studies, genetic toxicity studies, and 90-day repeated-dose feeding studies in rodents have all found DHM (and total flavonoid extracts dominated by DHM) to be toxicologically safe across a wide dose range, with no significant adverse effects on hematology, biochemistry, or pathology². Continuous administration for extended periods produced no observable negative effects in the studies that have looked at this carefully.

The CYP450 Drug-Interaction Caveat

This is the part of the safety profile that matters most for consumers on prescription medications. A 2020 in-vitro study of DHM's effects on human liver cytochrome P450 enzymes found that DHM has the potential to inhibit several CYP isoforms, including CYP3A4, CYP2E1, and CYP2D6³. Those three enzymes together metabolize a large fraction of commonly prescribed medications, including statins, some antidepressants, calcium channel blockers, and many others. The clinical significance of the in-vitro inhibition has not been fully characterized in vivo, but the signal is real enough that anyone on prescription medications should consult a clinician before starting a daily DHM supplement.

(the CYP450 interaction caveat is the part of the safety profile I most want consumers on prescription medications to read carefully, because it is the realistic concern.)

What "Long-Term" Means in This Context

The long-term human safety data on DHM specifically is thin. ClinicalTrials.gov lists only a handful of registered DHM clinical studies, and none of them have run for the multi-year periods that would generate long-term safety surveillance data². This is not unusual for the supplement category -- most flavonoid ingredients have similar gaps in long-term human safety data -- but it is honest to call out as a real limitation.

The long-term human data is still thin adn anyone with chronic conditions should talk to a clinician before adding a daily flavonoid supplement.

How H180 Handles This

The H180 product is positioned as an occasional-use supplement around moderate alcohol intake, not as a daily long-term flavonoid regimen. That use pattern stays within the time horizons covered by the existing safety literature on DHM. The CYP450 interaction caveat is included on the consumer-facing material so that anyone on prescription medications has the information they need to talk to their clinician.

What This Page Is Not Claiming

We are not claiming DHM is risk-free, that the long-term safety profile is fully characterized, or that drug interactions are negligible. The claim is bounded -- short-term safety is well-documented, animal toxicology is favorable across a wide dose range, the CYP450 interaction caveat is a real consideration for some consumers, and long-term human data remains a limitation that the broader flavonoid-supplement category shares.

For dose context, see DHM Dose-Response. For why the formula uses 1,500mg specifically, see the formula.